Comparison Chart: SGLT2 Inhibitors (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

November 16, 2020

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report

Objective(s)

Upon completion of this activity, the participant will be able to:

Review the efficacy of empagliflozin (Jardiance) in patients with heart failure

Select a term to see related articles canagliflozin dapagliflozin empagliflozin ertugliflozin Farxiga Forxiga Glyxambi Invokamet Invokana Jardiance linagliptin metformin Qtern Saxagliptin Segluromet sitagliptin Steglatro Steglujan Synjardy Xigduo

Updated May 17, 2021

View the Comparison Chart: SGLT2 Inhibitors
Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.